Search Result
Results for "
25 T cell
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Nombre del producto |
Target |
Áreas de investigación |
Chemical Structure |
-
- HY-14171
-
Bexarotene
Maximum Cited Publications
22 Publications Verification
LGD1069
|
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
-
- HY-145923
-
|
ABBV-CLS-484
|
Phosphatase
STAT
JAK
|
Cancer
|
|
Osunprotafib (ABBV-CLS-484) is an orally active and selective active site PTPN1 (IC50: 2.5 nM) and PTPN2(IC50: 1.8 nM) inhibitor. Osunprotafib has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction .
|
-
-
- HY-113962
-
|
7α,25-OHC
|
EBI2/GPR183
Endogenous Metabolite
|
Inflammation/Immunology
|
|
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC50=140 pM; Kd=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells .
|
-
-
- HY-153220
-
|
NX-2127
|
PROTACs
Btk
|
Inflammation/Immunology
Cancer
|
|
Zelebrudomide (NX-2127) (Compound 28) is an orally active PROTAC deggrader, targeting to Bruton’s Tyrosine Kinase (Btk). Zelebrudomide inhibits proliferation of BTK C481S mutant TMD8 cells, more effectively than Ibrutinib (HY-10997). Zelebrudomide catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) with of 25 nM and 54 nM, respectively. Zelebrudomide stimulates T cell activation and increases IL-2 production in primary human T Cells . (Pink: BTK ligand 10 (HY-168302); Black: (R)-4-(1-(Pyrrolidin-3-ylmethyl)piperidin-4-yl)aniline (HY-168348); Blue: Thalidomide 5-fluoride (HY-W087383)
|
-
-
- HY-12795
-
|
|
PI3K
Autophagy
|
Cancer
|
|
Vps34-IN-1 is a potent and selective inhibitor of class III Vps34 PI3K. Vps34-IN-1 inhibits phosphorylation of PtdIns by recombinant insect cell expressed Vps34-Vps15 complex with an IC50 of ~25 nM. Vps34-IN-1 can suppress SGK3 activation by reducing PtdIns(3)P levels via lowering phosphorylation of T-loop and hydrophobic motifs. Vps34-IN-1 modulates autophagy .
|
-
-
- HY-162065
-
N6F11
1 Publications Verification
|
Ferroptosis
|
Cancer
|
|
N6F11 is a selective ferroptosis inducer, and can selectively induce ferroptosis by targeting TRIM25-mediated GPX4 degradation in cancer cells while sparing immune cells. N6F11 initiates HMGB1-dependent antitumor immunity mediated by CD8 + T cells .
|
-
-
- HY-59219
-
|
|
Drug Intermediate
|
Cancer
|
|
Cyclopropylboronic acid is an intermediate. Cyclopropylboronic acid can be used to synthesize EGFR kinase inhibitor (Compound 25). Compound 25 has antiproliferative effects on EGFR mutant (EGFR Δ19del/T790M/C797S) cells. Cyclopropylboronic acid can be used in lung cancer research .
|
-
-
- HY-P990281
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1 λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can deplete CD25+ T cells. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can be used for the researches of immunology and inflammation, such as atopic dermatitis .
|
-
-
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
-
-
- HY-145776
-
-
-
- HY-P10953
-
|
PSP 29-mer, anti-inflammatory peptide
|
ERK
STAT
|
Inflammation/Immunology
|
|
Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). Fulipiftide induces the expansion of nuclear stem cell factor +TSPC by activating ERK2 and STAT3 signaling pathways. Fulipiftide has anti-inflammatory activity and can be used in the study of acute tendon injury .
|
-
-
- HY-P1585
-
|
Hgp100 (25-33)
|
MHC
|
Cancer
|
|
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma .
|
-
-
- HY-155978A
-
|
|
Tyrosinase
|
Inflammation/Immunology
|
|
RDN2150 (Compound 25) TFA is a ZAP-70 inhibitor (IC50: 14.6 nM). RDN2150 TFA covalently binds to the C346 residue of ZAP-70. RDN2150 TFA inhibits the expression of CD25 and CD69, and inhibits CD4 + T cell activation. RDN2150 TFA can be used for research of psoriasis .
|
-
-
- HY-P1684
-
|
FOXP3 inhibitor P60
|
NF-κB
Nuclear Factor of activated T Cells (NFAT)
|
Infection
Inflammation/Immunology
Cancer
|
|
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
|
-
-
- HY-160496
-
|
|
STAT
|
Cancer
|
|
STAT3-IN-25 (Compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 has the potential for pancreatic cancer research .
|
-
-
- HY-135898
-
|
|
DGK
|
Inflammation/Immunology
Cancer
|
|
DGK-IN-1 is a DGK inhibitor (DGKa/DGKz IC50: 0.65/0.25 μM). DGK-IN-1 is a T cell activator that can be used in cancer and viral infection research .
|
-
-
- HY-113618B
-
|
|
CRAC Channel
Interleukin Related
|
Cardiovascular Disease
|
|
RO2959 monohydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 monohydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 monohydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways .
|
-
-
- HY-W181026
-
|
|
Fluorescent Dye
|
Inflammation/Immunology
|
|
KLF10-IN-1 (#48-15) is a KLF10 inhibitor with an IC50 value of 40 μM for KLF10 reporter gene. KLF10-IN-1 can inhibit KLF10-DNA binding and transcriptional activity, block the conversion of CD4+CD25 T cells to CD4+CD25+T regulatory cells, and inhibit the expression of KLF10 target genes. KLF10-IN-1 can be used as a useful mechanistic probe to study KLF10-mediated effects and T regulatory cell biology .
|
-
-
- HY-P1585A
-
|
Hgp100 (25-33) TFA
|
MHC
|
Cancer
|
|
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma .
|
-
-
- HY-W010995
-
|
|
Wnt
Survivin
β-catenin
|
Cancer
|
|
2,5-Dimethylcelecoxib is an analogue of celecoxib (HY-14398) with anticancer activity but without COX-2 inhibitory activity. 2,5-Dimethylcelecoxib exerts its anti-cancer cell proliferation effect by inhibiting the core mechanism of the Wnt/β-catenin signaling pathway. 2,5-Dimethylcelecoxib also inhibits T-cell factor-dependent transcriptional activity and inhibits expression of the Wnt/β-catenin target gene products cyclin D1 and survivin .
|
-
-
- HY-171178
-
|
|
p38 MAPK
|
Cancer
|
|
DK2403 (compound 25) is a MAP2K7 inhibitor (IC50= 0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia .
|
-
-
- HY-115489
-
|
|
Ras
|
Cancer
|
|
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
|
-
-
- HY-115489A
-
|
|
Protein Prenyltransferase
|
Cancer
|
|
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
|
-
-
- HY-P1822
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
|
|
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg + T cells .
|
-
-
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
-
- HY-P5396A
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
-
- HY-155477
-
|
|
E1/E2/E3 Enzyme
|
Cancer
|
|
Cbl-b-IN-15 (compound 25) is an inhibitor of the RING finger E3 ligase Cbl (IC50: 15 nM). Cbl-b refers to Casitas B-lineage lymphoma proto-oncogene-b, which inhibits T-cell, natural killer (NK) cell, and B-cell activation. Cbl-b-IN-15 activates T cell function with EC50=0.41 μM .
|
-
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
-
- HY-155231
-
|
|
Elastase
|
Cancer
|
|
Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC50: 42.30 nM, Ki: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC50s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .
|
-
-
- HY-113618A
-
|
|
CRAC Channel
Interleukin Related
|
Cardiovascular Disease
|
|
RO2959 hydrochloride is a potent and selective CRAC channel inhibitor with an IC50 of 402 nM. RO2959 hydrochloride is a potent blocker of store operated calcium entry (SOCE) mediated by Orai1/Stim1 channels with an IC50 of 25 nM. RO2959 hydrochloride is also a potent inhibitor of human IL-2 production, and potently blocks T cell receptor triggered gene expression and T cell functional pathways .
|
-
-
- HY-P991000
-
|
AU-007; BD-8; BDG8
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-143305
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer .
|
-
-
- HY-155978
-
|
|
Tyrosinase
|
Inflammation/Immunology
|
|
RDN2150 (Compound 25) is a ZAP-70 inhibitor (IC50: 14.6 nM). RDN2150 covalently binds to the C346 residue of ZAP-70. RDN2150 inhibits the expression of CD25 and CD69, and inhibits CD4 + T cell activation. RDN2150 can be used for research of psoriasis .
|
-
-
- HY-112371
-
|
|
CDK
|
Cancer
|
|
(S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM) .
|
-
-
- HY-145923B
-
|
ABBV-CLS-484 hydrochloride
|
Phosphatase
|
Inflammation/Immunology
Cancer
|
|
Osunprotafib (ABBV-CLS-484) hydrochloride is an orally active and selective active site PTPN1 (IC50: 2.5 nM) and PTPN2(IC50: 1.8 nM) inhibitor. Osunprotafib hydrochloride has 6-8-fold weaker activity on PTPN9 and no detectable activity on SHP-1 or SHP-2. Osunprotafib hydrochloride increases the sensitivity of human cancer cell lines to IFNγ. Osunprotafib hydrochloride generates robust anti-tumor immunity by enhancing JAK-STAT signalling and reducing T cell dysfunction .
|
-
-
- HY-159123
-
|
|
MAP4K
|
Cancer
|
|
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .
|
-
-
- HY-P10835
-
|
|
LAG-3
|
Cancer
|
|
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
|
-
-
- HY-150610
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC50 values of 4.3, 6.6 and 25.6 nM against EGFR L858R/T790M/C797S, EGFR L858R/T790M, and EGFR 19del/T790M/C797S, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .
|
-
-
- HY-162360
-
|
|
Apoptosis
EGFR
Caspase
Bcl-2 Family
|
Cancer
|
|
EGFR-IN-109 (compound 4) is an EGFR inhibitor, with the IC50 values of 25.8 and 182.3 nM for EGFR WT and EGFR T790M, respectively. EGFR-IN-109 arrests the cancer cells’ growth at the G2/M phase and induces both early and late apoptosis. EGFR-IN-109 can be used in cancer research .
|
-
-
- HY-P10760
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
|
-
-
- HY-178448
-
|
|
EGFR
JAK
Ferroptosis
Apoptosis
Reactive Oxygen Species (ROS)
Cannabinoid Receptor
Glutathione Peroxidase
Caspase
|
Inflammation/Immunology
Cancer
|
|
EGFR-IN-178 is an orally active EGFR mutant inhibitor, exhibits highly selective inhibitory activity against mutants of the EGFR enzyme, including Del19 (IC50 = 3.4 nM), L858R/T790 M (IC50 = 2.9 nM), and Del19/T790 M (IC50 = 2.5 nM). EGFR-IN-178 has good activity against JAK2 (IC50 = 55.6 nM) and JAK3 (IC50 = 46.1 nM) kinases. EGFR-IN-178 can increase cellular lipid oxide MDA, meanwhile decrease GSH content, causing ferroptosis in cancer cells. EGFR-IN-178 promotes apoptosis by increasing cleaved caspase-3 expression. EGFR-IN-178 can inhibit the phosphorylation of EGFR protein and decrease the active form p-JAK2 for JAK2, induce an increase in intracellular ROS. EGFR-IN-178 can be used for the study of non-small cell lung cancer (NSCLC) .
|
-
-
- HY-144437
-
|
|
TGF-β Receptor
|
Cancer
|
|
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC50 values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease .
|
-
-
- HY-168963
-
|
|
PROTACs
Btk
Itk
p38 MAPK
|
Inflammation/Immunology
Cancer
|
|
PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC50 of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC50 of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC50 of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))
|
-
-
- HY-P1822A
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
|
|
BDC2.5 mimotope 1040-31 TFA, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg + T cells .
|
-
-
- HY-142517
-
|
|
EGFR
|
Cancer
|
|
EGFR-IN-25 is a potent EGFR inhibitor with IC50s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .
|
-
-
- HY-155051
-
|
|
Apoptosis
Histone Methyltransferase
|
Cancer
|
|
Antiproliferative agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC50: 0.11 μM). Antiproliferative agent-25 up-regulates hnRNP E1 protein level. Antiproliferative agent-25 forms H-bond interactions with SAM and E444 residue of PRMT5. Antiproliferative agent-25 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. Antiproliferative agent-25 has high clearances with T1/2 of only 21.8 and 4.7 min in human and rat liver microsomes .
|
-
-
- HY-146071
-
|
|
Parasite
|
Infection
|
|
Antitrypanosomal agent 5 (Compound 25)is a selective anti-trypanosomal agent with IC50s of 1 nM and 483.3 µM against T. brucei cell growth and HEK293 cells growth , respectively .
|
-
-
- HY-137936
-
|
|
Antibiotic
|
Infection
|
|
Terrecyclic acid is a sesquiterpene originally isolated from A. terreus with antibiotic and anticancer activity. It is active against S. aureus, B. subtilis, and M. roseus (MICs=25, 50, and 25 μg/mL, respectively). Terrecyclic acid induces a heat shock response, increases levels of reactive oxygen species (ROS), and inhibits NF-κB activity and cell growth in 3T3-Y9-B12 cells.2 In vivo, terrecyclic acid (0.1, 1, and 10 mg/ml) reduces the number of ascitic fluid tumor cells in a mouse model of P388 murine leukemia.
|
-
-
- HY-157055
-
|
|
PD-1/PD-L1
|
Cancer
|
|
PD-1-IN-25 (compound 43) is a potent PD-1/PD-L1 interaction inhibitor with an IC50 value of 10.2 nM in the HTRF assay. PD-1-IN-25 can promote CD8+ T cell activation through inhibiting PD-1/PD-L1 cellular signaling. PD-1-IN-25 delays the tumor growth .
|
-
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-161551
-
|
|
Biochemical Assay Reagents
|
Inflammation/Immunology
|
|
25-OH Vitamin D3/KLH is an antigen-adjuvant conjugate of 25-OH Vitamin D3 (HY-158285) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
-
- HY-150543
-
|
|
Steroid Sulfatase
|
Cancer
|
|
Steroid sulfatase-IN-3 (compound 1q) is a potent STS (Steroid sulfatase) inhibitor, with an IC50 of 25.8 nM. Steroid sulfatase-IN-3 shows antiproliferative activity against T-47D estrogen-dependent breast cancer cells, with an IC50 of 1.04 µM .
|
-
- HY-P5930
-
|
MDM2 32-46
|
Ligands for E3 Ligase
|
Cancer
|
|
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 + T cell responses .
|
-
- HY-155745
-
|
|
Apoptosis
|
Cancer
|
|
Antitumor agent-115 (SS-12) is an effective anti-tumor compound with an IC50 value of 0.34 μM-24.14 μM for cell line 4T1. Antitumor agent-115 can block the cell cycle of mouse breast cancer cell line 4T1, reduce the mitochondrial membrane potential, and induce apoptosis, and the IC50 value is 8-25 μmol/L for cell viability. Antitumor agent-115 can be used for breast cancer research .
|
-
- HY-137632
-
|
|
PKA
|
Cancer
|
|
Sp-8-Cl-cAMPS is an analog of cAMP (HY-B1511) and a derivative of Sp-8-Cl-cAMP. Sp-8-Cl-cAMPS inhibits the growth of human leukemia cell HL-60 and colon cancer cell LS-174T, with IC50 of 8-100 μM. Sp-8-Cl-cAMPS activates the protein kinases cAKI and cAKII, with Ka of 0.25 and 3.2 μM .
|
-
- HY-161255
-
|
|
NO Synthase
|
Inflammation/Immunology
|
|
3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4 +CD25 + T cells expression . 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide .
|
-
- HY-156570
-
|
|
DGK
|
Inflammation/Immunology
Cancer
|
|
DGKα-IN-3 (example 25) is a DGKα inhibitor with the IC50 of 283 nM, extracted from patent WO2021105115. DGKα-IN-2 significantly enhances the anti-tumor effect of anti-PD-1 by increasing the proliferation and function of T cells. DGKα-IN-2 has the potential for cancer and immunology study.
|
-
- HY-117935
-
|
|
Ras
|
Cancer
|
|
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM .
|
-
- HY-164503
-
|
NEP010
|
EGFR
|
Cancer
|
|
Neptinib (NEP010) is an orally active derivative of Afatinib (HY-10261) that has stronger antitumor activity than Afatinib (HY-10261) by improving pharmacokinetics. Neptinib has a significant inhibitory effect on tumor growth in mouse non-small cell lung cancer models with different EGFR mutations. Neptinib has a certain inhibitory effect on the EGFR kinase family, with IC50 values ??of 0.24 nM, 7.25 nM, 0.46 nM and 1.79 nM for EGFR wt, EGFR L858R/T790M, EGFR L858R and EGFR T790M, respectively .
|
-
- HY-14171R
-
|
LGD1069 (Standard)
|
Reference Standards
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene (Standard) is the analytical standard of Bexarotene. This product is intended for research and analytical applications. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
- HY-14171S2
-
|
LGD1069-13C6
|
Isotope-Labeled Compounds
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene- 13C6 (LGD1069- 13C6) is 13C labeled Bexarotene. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
- HY-W777169
-
|
LGD1069-13C4
|
Isotope-Labeled Compounds
RAR/RXR
Autophagy
|
Cancer
|
|
Bexarotene- 13C4 (LGD1069- 13C4) is the 13C-labeled Bexarotene (HY-14171). Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
- HY-151464
-
|
|
SHP2
Phosphatase
HDAC
|
Inflammation/Immunology
Cancer
|
|
SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch .
|
-
- HY-162103
-
|
|
TAM Receptor
Apoptosis
|
Cancer
|
|
Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC50=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC50=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .
|
-
- HY-126638
-
|
NSC 324645
|
Parasite
|
Infection
|
|
Marcfortine A is an indole alkaloid originally isolated from P. roqueforti. It has nematocidal activity against the parasitic nematode H. contortus (LD99=0.06 μg/mL) and inhibits motility of adult worms (EC50=2 μM). Marcfortine A eliminates H. contortus, T. colubriformis, and O. ostertagi from experimentally infected jirds (ED95s=0.33, 0.11, and 2.5 mg/animal, respectively). It dose-dependently inhibits nicotine-induced calcium mobilization in SH-SY5Y and TE-671 cells expressing α3 subunit-containing human nicotinic acetylcholine receptors (nAChRs) and muscle-type nAChRs, respectively.
|
-
- HY-183604
-
|
|
Deubiquitinase
|
Cancer
|
|
T-10531 is a selective USP25/USP28 inhibitor. T-10531 exhibits an IC50 of 0.03 μM and a Kd of 0.2 μM against human USP25, as well as an IC50 of 0.12 μM and a Kd of 0.06 μM against human USP28. T-10531 inhibits USP25/USP28 activity and induces the degradation of USP25 via the proteasomal pathway, without inhibiting other deubiquitinases. T-10531 can be used in the research of squamous cell carcinoma, colorectal cancer, gastric cancer, triple-negative breast cancer and pancreatic cancer .
|
-
- HY-169413
-
|
|
Akt
|
Cancer
|
|
AKT-IN-25 (Compound 14a) is an inhibitor for Akt, that inhibits the phosphorylation of Akt, and thereby inhibits the PI3K/Akt/mTOR signaling pathway. AKT-IN-25 arrests the cell cycle at G1 phase, inhibits the cell migration of PANC-1, and inhibits the proliferation of cancer cells PANC-1, PATU-T, and SUIT-2 with IC50s of 3.05, 1.32, and 3.85 μM, respectively .
|
-
- HY-P992029
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
|
-
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
- HY-N0990
-
|
|
Others
|
Cancer
|
|
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC50 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .
|
-
- HY-P11490
-
|
|
MDM-2/p53
|
Inflammation/Immunology
Cancer
|
|
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic T cells and suppressing CD4 +/CD25 + regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
|
-
- HY-N16980
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
(7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one (compound 4) is a novel neolignan anti-inflammatory agent. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one has an IC50 of 25.2 μM against TGF-β-induced hepatic stellate cells (HSC-T6). (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one may be related to blocking excessive cell proliferation in the process of liver fibrosis and can be used in the study of liver fibrosis-related diseases. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one can be naturally extracted from the dried aerial parts of Penthorum chinense Pursh .
|
-
| Cat. No. |
Nombre del producto |
Type |
-
- HY-59219
-
|
|
Biochemical Assay Reagents
|
|
Cyclopropylboronic acid is an intermediate. Cyclopropylboronic acid can be used to synthesize EGFR kinase inhibitor (Compound 25). Compound 25 has antiproliferative effects on EGFR mutant (EGFR Δ19del/T790M/C797S) cells. Cyclopropylboronic acid can be used in lung cancer research .
|
-
- HY-161551
-
|
|
Biochemical Assay Reagents
|
|
25-OH Vitamin D3/KLH is an antigen-adjuvant conjugate of 25-OH Vitamin D3 (HY-158285) and Keyhole Limpet Hemocyanin (KLH). By conjugating the antigen with the protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and it can enhance cross-presentation and the generation of antigen-specific T cells.
|
| Cat. No. |
Nombre del producto |
Target |
Research Area |
-
- HY-P10953
-
|
PSP 29-mer, anti-inflammatory peptide
|
ERK
STAT
|
Inflammation/Immunology
|
|
Fulipiftide is a short peptide derived from pigment epithelium-derived factor (PEDF). Fulipiftide induces the expansion of nuclear stem cell factor +TSPC by activating ERK2 and STAT3 signaling pathways. Fulipiftide has anti-inflammatory activity and can be used in the study of acute tendon injury .
|
-
- HY-P1585
-
|
Hgp100 (25-33)
|
MHC
|
Cancer
|
|
Gp100 (25-33), human (Hgp100 (25-33)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human has immunogenicity and induces specific T cells. Gp100 (25-33), human can be used for the cancer research, such as melanoma .
|
-
- HY-P1684
-
|
FOXP3 inhibitor P60
|
NF-κB
Nuclear Factor of activated T Cells (NFAT)
|
Infection
Inflammation/Immunology
Cancer
|
|
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4 +CD25 +Foxp3 + T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome .
|
-
- HY-P1585A
-
|
Hgp100 (25-33) TFA
|
MHC
|
Cancer
|
|
Gp100 (25-33), human TFA (Hgp100 (25-33) (TFA)) is the amino acids 25-33 fragment of the human melanoma antigen. Gp100 (25-33), human TFA is a 9-amino acid (AA) epitope restricted by MHC class I H-2D b and recognized by the T cells. Gp100 (25-33), human TFA has immunogenicity and induces specific T cells. Gp100 (25-33), human TFA can be used for the cancer research, such as melanoma .
|
-
- HY-P1822
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
|
|
BDC2.5 mimotope 1040-31, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg + T cells .
|
-
- HY-P5396A
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-P5488
-
|
|
Peptides
|
Others
|
|
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
|
-
- HY-P10512
-
|
|
Peptides
|
Others
|
|
BDC2.5 mimotope is a potent antigen-mimicking peptide that can activate CD4+ T cell populations that have the same antigen recognition properties as BDC2.5 cells. BDC2.5 mimotope can be used to study the prevention or treatment of type 1 diabetes by targeting specific T cell populations .
|
-
- HY-P10835
-
|
|
LAG-3
|
Cancer
|
|
LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8 + T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer .
|
-
- HY-P10760
-
|
|
Peptide-Drug Conjugates (PDCs)
|
Cancer
|
PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
|
-
- HY-P1822A
-
|
|
Transmembrane Glycoprotein
|
Metabolic Disease
|
|
BDC2.5 mimotope 1040-31 TFA, a BDC2.5 TCR reactive peptide, is a strong agonistic peptide for diabetogenic T cell clone BDC2.5, and the 1040-31 peptide is specific for BDC 2.5 TCR Tg + T cells .
|
-
- HY-P1910
-
|
|
Peptides
|
Metabolic Disease
|
|
BDC2.5 mimotope 1040-51 is a mimotope peptide for diabetogenic T cell clone BDC2.5. isolated from non-obese diabetic mice .
|
-
- HY-P5396
-
|
|
Amino Acid Decarboxylase
|
Others
|
|
GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells .
|
-
- HY-P5930
-
|
MDM2 32-46
|
Ligands for E3 Ligase
|
Cancer
|
|
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 + T cell responses .
|
-
- HY-P11490
-
|
|
MDM-2/p53
|
Inflammation/Immunology
Cancer
|
|
DPMI-ω is a dual-specificity d-peptide antagonist of oncogenic proteins MDM2 and MDMX. DPMI-ω, upon fabrication on gold nanoparticles, efficiently traverses tumor cells and kills them by reactivating the p53 signaling pathway. DPMI-ω can disrupte the p53-MDM2/MDMX complex. DPMI-ω can inhibit B16 melanoma growth and induce cells G0/G1 phase arrest. DPMI-ω can augment the efficacy of immunotherapy by expanding CD3 +/CD8 + cytotoxic T cells and suppressing CD4 +/CD25 + regulatory T cells companied with anti-PD1 antibody. DPMI-ω can be used for research of melanoma .
|
| Cat. No. |
Nombre del producto |
-
- HY-K2014
-
|
|
|
MCE PEI Transfection Reagent is designed based on 25 kDa PEI. It has high-efficiency, low-toxicity, strong-stability, and is suitable for many cell types, such as HEK-293、HEK-293T、CHO-K1、COS-1、COS-7、NIH/3T3、Sf9、HepG2 and HeLa et, even some hard-to-transfect cells. It can also be applied to large-scale recombinant protein expression and virus production. The 1 mL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.
|
| Cat. No. |
Nombre del producto |
Target |
Research Area |
Image |
-
- HY-P990281
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) is a rat-derived IgG1 λ type antibody inhibitor, targeting to mouse CD25/IL-2Rα. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can deplete CD25+ T cells. Anti-Mouse CD25/IL-2Rα Antibody (PC-61.5.3) can be used for the researches of immunology and inflammation, such as atopic dermatitis .
|
-
(5)
-
- HY-108738
-
|
Ro 24-7375
|
Interleukin Related
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
Daclizumab (Ro 24-7375) is a humanized, monoclonal antibody that blocks CD25 (α-subunit of the high-affinity interleukin-2 receptor (IL-2R-HA)). Daclizumab inhibits effector T cell activation, regulatory T cell (Treg) expansion and survival, and activation-induced T-cell apoptosis. Daclizumab increases IL-2 bioavailability to bind to the intermediate-affinity IL-2R (IL-2R-IA), driving the expansion of anti-inflammatory CD56bright natural killer (NK) cells. Daclizumab can be used for multiple sclerosis and cancer research .
|
-
(5)
-
- HY-P991110
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-Mouse CD25 Antibody (7D4) is a mouse IgG2 monoclonal antibody targeting CD25. Anti-Mouse CD25 Antibody (7D4) enables the isolation of naive CD4 + T cells by depleting CD25-expressing cells .
|
-
(5)
-
- HY-P991455
-
|
|
TNF Receptor
|
Cancer
|
|
PTX-35 is a human IgG monoclonal antibody (mAb) targeting TNFRSF25. PTX-35 reduces the suppressive activity of regulatory T cells and enhances CD4+ T cell effector responses in a mouse melanoma model. PTX-35 can be used in Islet cell transplant rejection and Solid tumours research. Recommended isotype control: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
-
- HY-P991000
-
|
AU-007; BD-8; BDG8
|
Interleukin Related
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Imneskibart (AU-007) is a human monoclonal antibody that binds to the CD25-binding epitope of interleukin-2 (IL-2), blocking the binding of IL-2 to the trimeric IL-2 receptor while retaining the ability to bind to the dimeric IL-2 receptor. Imneskibart expands effector T cell and NK cell populations, reduces regulatory T cells, increases the effector T cell/regulatory T cell ratio, and alleviates vascular leakage. Imneskibart can be used in research related to melanoma and non-small cell lung cancer. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P992029
-
|
|
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
RTX-003 is a monoclonal antibody targeting CD25. RTX-003 induces the death of regulatory T cells (Tregs) by targeting the IL-2 receptor α chain (CD25), and can enhance anti-tumor immune responses.
|
-
(5)
-
- HY-P991762
-
|
|
Transmembrane Glycoprotein
|
Inflammation/Immunology
|
|
Anti-Rat CD4 Antibody (W3/25) reacts with rat CD4. Anti-Rat CD4 Antibody (W3/25) inhibits CD4+ T cell activation by downregulating the CD4 molecule on the surface of lymphocytes. Anti-Rat CD4 Antibody (W3/25) inhibits antigen-induced T cell proliferation and IL2 production in MLR experiments. Anti-Rat CD4 Antibody (W3/25) can be used for the study of experimental allergic encephalomyelitis (EAE). Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
|
-
(5)
| Cat. No. |
Nombre del producto |
Category |
Target |
Chemical Structure |
-
- HY-113962
-
-
-
- HY-126638
-
|
NSC 324645
|
Human Gut Microbiota Metabolites
Microorganisms
Endogenous metabolite
Source Classification
|
Parasite
|
|
Marcfortine A is an indole alkaloid originally isolated from P. roqueforti. It has nematocidal activity against the parasitic nematode H. contortus (LD99=0.06 μg/mL) and inhibits motility of adult worms (EC50=2 μM). Marcfortine A eliminates H. contortus, T. colubriformis, and O. ostertagi from experimentally infected jirds (ED95s=0.33, 0.11, and 2.5 mg/animal, respectively). It dose-dependently inhibits nicotine-induced calcium mobilization in SH-SY5Y and TE-671 cells expressing α3 subunit-containing human nicotinic acetylcholine receptors (nAChRs) and muscle-type nAChRs, respectively.
|
-
-
- HY-N0990
-
|
|
Anthraquinones
Morinda citrifolia Linn.
Rubiaceae
Plants
Source Classification
|
Others
|
|
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC50 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .
|
-
-
- HY-N16980
-
|
|
Structural Classification
Phenols
Polyphenols
Saxifragaceae
Plants
Penthorum chinense Pursh
Source Classification
|
TGF-beta/Smad
|
|
(7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one (compound 4) is a novel neolignan anti-inflammatory agent. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one has an IC50 of 25.2 μM against TGF-β-induced hepatic stellate cells (HSC-T6). (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one may be related to blocking excessive cell proliferation in the process of liver fibrosis and can be used in the study of liver fibrosis-related diseases. (7'E,8S)-2',4,8-Trihydroxy-3-methoxy-2,4'-epoxy-8,5'-neolign-7'-en-7-one can be naturally extracted from the dried aerial parts of Penthorum chinense Pursh .
|
-
| Cat. No. |
Nombre del producto |
Chemical Structure |
-
- HY-14171S2
-
|
|
|
Bexarotene- 13C6 (LGD1069- 13C6) is 13C labeled Bexarotene. Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
-
- HY-W777169
-
|
|
|
Bexarotene- 13C4 (LGD1069- 13C4) is the 13C-labeled Bexarotene (HY-14171). Bexarotene (LGD1069) is a high-affinity and selective retinoid X receptors (RXR) agonist with EC50s of 33, 24, 25 nM for RXRα, RXRβ, and RXRγ, respectively. Bexarotene shows limited affinity for RAR receptors (EC50 >10000 nM) . Bexarotene can be used for the research of cutaneous T-cell lymphoma.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Nombre del producto:
- Cat. No.:
- Cantidad:
- MCE Japan Authorized Agent:
